Jump to content

In need of some encouraging news…


JoWell

Recommended Posts

Hi JoWell,

I'm not sure how to answer your question as I neither know what new drugs would be best for you nor what drugs you've already tried. But, Lungevity does have an area where clinical trials are highlighted and there may be something there for you that could be helpful.  You can find the "Find a Clinical Trial" section here.  You can even speak to a "Clinical Trial Navigator" if you choose.  Some of the others are may know specific drugs that are new and I hope you find something helpful soon.

Link to comment
Share on other sites

  • 2 weeks later...

Here is just a 12 month snapshot in NSCLC

 

Four New Medications For Lung Cancer Are Now Available
The FDA approved or granted accelerated approval to four new treatments for lung cancer in 2021. The four treatments — Tepmetko (tepotinib), Rybrevant (amivantamab-vmjw), Lumakras (sotorasib), and Exkevity (mobocertinib) — offer new therapies for cancers with few options.

Accelerated approval is used for drugs for serious medical conditions with no or few treatment options. Accelerated approval is based on a “surrogate endpoint,” or marker that predicts a clinical benefit to the drug. Drugs granted accelerated approval must still undergo study to provide the data required for a full approval.

Tepmetko
Tepmetko was given accelerated approval by the FDA on Feb. 3 for treating metastatic non-small cell lung cancer (NSCLC) with mutations in the mesenchymal-epithelial transition (MET) gene. It is the first oral MET inhibitor developed to treat NSCLC.

Rybrevant
Rybrevant was approved by the FDA on May 21 as the first available treatment for NSCLC cases with epidermal growth factor receptor (EGFR) exon 20 insertion mutations. Rybrevant is administered as an intravenous infusion.

Rybrevant was approved alongside a genetic test called Guardant360 CDx that is used to confirm that a person’s cancer has an EGFR exon 20 insertion.

Lumakras
On May 28, the FDA approved Lumakras for treating NSCLC with a specific mutation known as KRAS G12C. Lumakras is the first targeted therapy approved for this mutation, which has been considered resistant to treatment. It is taken orally.

Exkivity
Exkivity received accelerated approval on Sept. 15 as a new treatment for NSCLC with EGFR exon 20 insertions. Exkivity is the first oral therapy available to treat NSCLC with EGFR exon 20 insertions.

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Guest
Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

×
×
  • Create New...

Important Information

By using this site, you agree to our Terms of Use.